bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
Authors: Salama April K.S. , Palta Manisha , Rushing Christel N. , Selim M. Angelica , Linney Kristen N. , Czito Brian G. , Yoo David S. , Hanks Brent A. , Beasley Georgia M. , Mosca Paul J. , Dumbauld Chelsae , Steadman Katelyn N. , Yi John S. , Weinhold Kent J. , Tyler Douglas S. , Lee Walter T. , Brizel David M.
Published: April 2023

Trial Schema
Figure S5 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

Final PK covariate associations
Supplementary Figure S5 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S5. SX-682 treatment does not alter the proliferation of PMN-MDSC within MOC2 tumors.
Supplementary Figure S4 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S4. Ex vivo SX-682 exposure does not reduce the viability of sorted MDSC
Supplementary File from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

Tissue expression datasets
Table S7 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S7
Supplementary Tables from Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials
Authors: Upadhyaya Santhosh A. , Robinson Giles W. , Onar-Thomas Arzu , Orr Brent A. , Johann Pascal , Wu Gang , Billups Catherine A. , Tatevossian Ruth G. , Dhanda Sandeep Kumar , Srinivasan Ashok , Broniscer Alberto , Qaddoumi Ibrahim , Vinitsky Anna , Armstrong Gregory T. , Bendel Anne E. , Hassall Tim , Partap Sonia , Fisher Paul G. , Crawford John R. , Chintagumpala Murali , Bouffet Eric , Gururangan Sridharan , Mostafavi Roya , Sanders Robert P. , Klimo Paul , Patay Zoltan , Indelicato Daniel J. , Nichols Kim E. , Boop Frederick A. , Merchant Thomas E. , Kool Marcel , Ellison David W. , Gajjar Amar
Published: April 2023

Supplementary information
Supplementary Information from Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Authors: Tolaney Sara M. , Kalinsky Kevin , Kaklamani Virginia G. , D'Adamo David R. , Aktan Gursel , Tsai Michaela L. , O'Regan Ruth M. , Kaufman Peter A. , Wilks Sharon T. , Andreopoulou Eleni , Patt Debra A. , Yuan Yuan , Wang Grace , Savulsky Claudio , Xing Dongyuan , Kleynerman Ella , Karantza Vassiliki , Diab Sami
Published: April 2023

Supplementary Information
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Figure 1. (a) Schematic depicting 2D amplitude differentiation between mutually exclusive C228T and C250T mutations
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Table 3
Supplementary Data from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
Authors: Keenan Tanya E. , Li Tianyu , Vallius Tuulia , Guerriero Jennifer L. , Tayob Nabihah , Kochupurakkal Bose , Davis Janae , Pastorello Ricardo , Tahara Rie K. , Anderson Leilani , Conway Jake , He Meng X. , Shannon Erin , Godin Robert E. , Sorger Peter K. , D'Andrea Alan , Overmoyer Beth , Winer Eric P. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Shapiro Geoffrey I. , Tolaney Sara M.
Published: April 2023

Supplemental methods, results, figures, tables, and references
Supplemental Figure 1 from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Authors: Schoenfeld Adam J. , Chan Joseph M. , Kubota Daisuke , Sato Hiroki , Rizvi Hira , Daneshbod Yahya , Chang Jason C. , Paik Paul K. , Offin Michael , Arcila Maria E. , Davare Monika A. , Shinde Ujwal , Pe'er Dana , Rekhtman Natasha , Kris Mark G. , Somwar Romel , Riely Gregory J. , Ladanyi Marc , Yu Helena A.
Published: April 2023

Supplemental Figure 1. Compound EGFR S768I+V769L (EGFR-SV768IL) mutations confer resistance to osimertinib.
Supplementary Data from Characterizing CDK12-Mutated Prostate Cancers
Authors: Rescigno Pasquale , Gurel Bora , Pereira Rita , Crespo Mateus , Rekowski Jan , Rediti Mattia , Barrero Maialen , Mateo Joaquin , Bianchini Diletta , Messina Carlo , Fenor de la Maza Maria D. , Chandran Khobe , Carmichael Juliet , Guo Christina , Paschalis Alec , Sharp Adam , Seed George , Figueiredo Ines , Lambros Maryou , Miranda Susana , Ferreira Ana , Bertan Claudia , Riisnaes Ruth , Porta Nuria , Yuan Wei , Carreira Suzanne , de Bono Johann S.
Published: April 2023

Legends for supplementary figures and tables.
Supplemental Tables and Figure Caption from Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Authors: Loree Jonathan M. , Dowers Anthony , Tu Dongsheng , Jonker Derek J. , Edelstein Daniel L. , Quinn Hannah , Holtrup Frank , Price Timothy , Zalcberg John R. , Moore Malcolm J. , Karapetis Christos S. , O'Callaghan Chris J. , Waring Paul , Kennecke Hagen F. , Hamilton Stanley R. , Kopetz Scott
Published: April 2023

Supplemental Tables and Figure Caption
Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Supplementary Tables
Supplementary Table 3 from Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
Authors: Kanikarla Marie Preeti , Haymaker Cara , Parra Edwin Roger , Kim Young Uk , Lazcano Rossana , Gite Swati , Lorenzini Daniele , Wistuba Ignacio I. , Tidwell Rebecca S. Slack , Song Xiaofei , Foo Wai Chin , Maru Dipen M. , Chun Yun Shin , Futreal Andy , Kee Bryan , Menter David , Solis Luisa , Tzeng Ching-Wei , Parseghian Christine , Raghav Kanwal , Morris Van , Chang Chia-Chi , Jenq Robert , Tam Alda , Bernatchez Chantale , Kopetz Scott , Vauthey Jean-Nicolas , Overman Michael J.
Published: April 2023

DEG and GSEA gene set analysis post vs pre treatment
Supplementary Table 1 and 2 from Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
Authors: Kanikarla Marie Preeti , Haymaker Cara , Parra Edwin Roger , Kim Young Uk , Lazcano Rossana , Gite Swati , Lorenzini Daniele , Wistuba Ignacio I. , Tidwell Rebecca S. Slack , Song Xiaofei , Foo Wai Chin , Maru Dipen M. , Chun Yun Shin , Futreal Andy , Kee Bryan , Menter David , Solis Luisa , Tzeng Ching-Wei , Parseghian Christine , Raghav Kanwal , Morris Van , Chang Chia-Chi , Jenq Robert , Tam Alda , Bernatchez Chantale , Kopetz Scott , Vauthey Jean-Nicolas , Overman Michael J.
Published: April 2023

Treatment related adverse events and list of antibodies used.
eFigure4 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Kaplan-Meier curves for progression-free and overall survival for high TMB {greater than or equal to}10 mutations/Mb in chemotherapy-treated mTNBC. (A) Progression-free survival and (B) overall survival by tumor mutational burden <10 vs. {greater than or equal to}10 mutations/megabase.
Supplementary Table S2 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Table S2. Post-progression therapies according to treatment arm.
Supplementary Table S1 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Table S1. Efficacy and activity measures in intention-to-treat population.
Supplementary Figure S6 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S6. Mean changes from baseline by study arm in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 symptom items.
Supplementary Data from CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer
Authors: Williams Edward H. , Flint Thomas R. , Connell Claire M. , Giglio Daniel , Lee Hassal , Ha Taehoon , Gablenz Eva , Bird Nicholas J. , Weaver James M.J. , Potts Harry , Whitley Cameron T. , Bookman Michael A. , Lynch Andy G. , Meyer Hannah V. , Tavaré Simon , Janowitz Tobias
Published: April 2023

Excel file containing Tables S7, S9-15, S18
Table S5 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

List of BRCA1/2 deleterious (red) and reversion (blue) mutations summarized in Fig 3C.
Table S3 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Positive percent agreement (PPA) between patient-matched cancer tissue and liquid biopsies.
Figure S8 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Variant allele fractions of DDR genes.
Supplementary Figure S2 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
Authors: Deegen Petra , Thomas Oliver , Nolan-Stevaux Olivier , Li Shyun , Wahl Joachim , Bogner Pamela , Aeffner Famke , Friedrich Matthias , Liao Michael Z. , Matthes Katja , Rau Doris , Rattel Benno , Raum Tobias , Kufer Peter , Coxon Angela , Bailis Julie M.
Published: April 2023

Figure S2. Enzalutamide increases PSMA expression levels and may enhance AMG 160-dependent cytotoxicity.
Supplementary Data from Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction
Authors: Kobatake Kohei , Ikeda Ken-ichiro , Nakata Yuichiro , Yamasaki Norimasa , Ueda Takeshi , Kanai Akinori , Sentani Kazuhiro , Sera Yasuyuki , Hayashi Tetsutaro , Koizumi Miho , Miyakawa Yoshihiko , Inaba Toshiya , Sotomaru Yusuke , Kaminuma Osamu , Ichinohe Tatsuo , Honda Zen-ichiro , Yasui Wataru , Horie Shigeo , Black Peter C. , Matsubara Akio , Honda Hiroaki
Published: April 2023

Supplementary Information: Tables S1, S2, S3, S4 (gene set enrichment analyses); Figures S1, S2, S3, S4
Figure S4 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Genomic landscape of prostate cancer in liquid and tissue biopsy.
Figure S3 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Alterations in PI3K, WNT, RAS and FGFR components in liquid biopsy.
Figure S2 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Genomic landscape of prostate cancer in liquid biopsies
Supplementary fig 5 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Authors: Wang Chunmeng , Liu Yang , Dong Liang , Li Xiang , Yang Qingming , Brock Malcolm V. , Mei Qian , Liu Jiejie , Chen Meixia , Shi Fengxia , Liu Miao , Nie Jing , Han Weidong
Published: April 2023

Figure 5. PD-1 level in tumor-infiltrated T-cells.
Supplementary fig 4 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Authors: Wang Chunmeng , Liu Yang , Dong Liang , Li Xiang , Yang Qingming , Brock Malcolm V. , Mei Qian , Liu Jiejie , Chen Meixia , Shi Fengxia , Liu Miao , Nie Jing , Han Weidong
Published: April 2023

Figure 4. Ratio of peripheral central memory T-cells and association with progression-free survival.
Supplementary fig 2 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Authors: Wang Chunmeng , Liu Yang , Dong Liang , Li Xiang , Yang Qingming , Brock Malcolm V. , Mei Qian , Liu Jiejie , Chen Meixia , Shi Fengxia , Liu Miao , Nie Jing , Han Weidong
Published: April 2023

Figure 2. Progression-free survival.
Supplementary fig 1 from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Authors: Wang Chunmeng , Liu Yang , Dong Liang , Li Xiang , Yang Qingming , Brock Malcolm V. , Mei Qian , Liu Jiejie , Chen Meixia , Shi Fengxia , Liu Miao , Nie Jing , Han Weidong
Published: April 2023

Figure 1. Anti-tumor response.
Supplemental Figure S3 from Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Authors: Xu Wenxin , Puligandla Mäneka , Halbert Brian , Haas Naomi B. , Flaherty Keith T. , Uzzo Robert G. , Dutcher Janice P. , DiPaola Robert S. , Sabbisetti Venkata , Bhatt Rupal S.
Published: April 2023

Association between paired baseline and C2D1 plasma KIM-1 values
Supplemental Figure S2 from Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Authors: Xu Wenxin , Puligandla Mäneka , Halbert Brian , Haas Naomi B. , Flaherty Keith T. , Uzzo Robert G. , Dutcher Janice P. , DiPaola Robert S. , Sabbisetti Venkata , Bhatt Rupal S.
Published: April 2023

Relationship between baseline KIM-1 and clinical/pathologic features
Figure S1-S10 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
Authors: Okura Naoko , Nishioka Naoya , Yamada Tadaaki , Taniguchi Hirokazu , Tanimura Keiko , Katayama Yuki , Yoshimura Akihiro , Watanabe Satoshi , Kikuchi Toshiaki , Shiotsu Shinsuke , Kitazaki Takeshi , Nishiyama Akihiro , Iwasaku Masahiro , Kaneko Yoshiko , Uchino Junji , Uehara Hisanori , Horinaka Mano , Sakai Toshiyuki , Tanaka Kohei , Kozaki Ryohei , Yano Seiji , Takayama Koichi
Published: April 2023

Figure S1-S10
Supplementary Data from Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Authors: Xu Jianming , Shen Jie , Gu Shanzhi , Zhang Yun , Wu Lihua , Wu Jian , Shao Guoliang , Zhang Yanqiao , Xu Li , Yin Tao , Liu Jingfeng , Ren Zhenggang , Xiong Jianping , Mao Xianhai , Zhang Ling , Yang Jiayin , Li Lequn , Chen Xiaoming , Wang Zhiming , Gu Kangsheng , Chen Xi , Pan Zhanyu , Ma Kuansheng , Zhou Xinmin , Yu Zujiang , Li Enxiao , Yin Guowen , Zhang Xiao , Wang Shuni , Wang Quanren
Published: April 2023

Supplementary Methods, Supplementary Figure S1-4, Supplementary Table S1-8
Supplementary Tables S1-S8 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Authors: Karn Thomas , Meissner Tobias , Weber Karsten E. , Solbach Christine , Denkert Carsten , Engels Knut , Fasching Peter A. , Sinn Bruno V. , Schrader Iris , Budczies Jan , Marmé Frederik , Müller Volkmar , Holtrich Uwe , Gerber Bernd , Schem Christian , Young Brandon M. , Hanusch Claus , Stickeler Elmar , Huober Jens , van Mackelenbergh Marion , Leyland-Jones Brian , Fehm Tanja , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: April 2023

Tab.S1: Specific analysis roles and blinding status of contributing teams. Tab.S2: Pre-defined analytical aims of the study. Tab.S3: Comparison of clinical parameters of the complete trial cohort and the RNA-Seq cohorts. Tab.S4: Gene lists of signatures. Tab.S5: Core genes of the hypoxia signature cluster from different datasets with correlated expression. Tab.S6: Accuracy of IHC detection of NDRG1 as marker of the hypoxia signature. Tab.S7: Comparison of hormone receptor status from RNA-Seq and IHC. Tab.S8: Comparison of Molecular Subtyping between High Quality and Low Quality Samples. Tab.S9: Univariate logistic regression of pCR by molecular markers (N=221 High Quality samples). Tab.S10: Multivariate logistic regression of pCR with NDRG1 from TMA analysis.
Figure S7 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Authors: Karn Thomas , Meissner Tobias , Weber Karsten E. , Solbach Christine , Denkert Carsten , Engels Knut , Fasching Peter A. , Sinn Bruno V. , Schrader Iris , Budczies Jan , Marmé Frederik , Müller Volkmar , Holtrich Uwe , Gerber Bernd , Schem Christian , Young Brandon M. , Hanusch Claus , Stickeler Elmar , Huober Jens , van Mackelenbergh Marion , Leyland-Jones Brian , Fehm Tanja , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: April 2023

Poor detection of NDRG1 expression signal in TMA analysis
Figure S4 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Authors: Karn Thomas , Meissner Tobias , Weber Karsten E. , Solbach Christine , Denkert Carsten , Engels Knut , Fasching Peter A. , Sinn Bruno V. , Schrader Iris , Budczies Jan , Marmé Frederik , Müller Volkmar , Holtrich Uwe , Gerber Bernd , Schem Christian , Young Brandon M. , Hanusch Claus , Stickeler Elmar , Huober Jens , van Mackelenbergh Marion , Leyland-Jones Brian , Fehm Tanja , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: April 2023

Para-necrotic expression of NDRG1 in TNBC
Supplementary Methods from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Supplementary Material and Methods
Figure S1 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Schematic diagrams showing the protein structure of the anti-hu4-1BB IgG (a), and the gene layout (b) and protein structure (c) of the anti-hu4-1BB trimerbody.
Supplementary Tables from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Authors: Jhaveri Komal , Chang Matthew T. , Juric Dejan , Saura Cristina , Gambardella Valentina , Melnyk Anton , Patel Manish R. , Ribrag Vincent , Ma Cynthia X. , Aljumaily Raid , Bedard Philippe L. , Sachdev Jasgit C. , Dunn Lara , Won Helen , Bond John , Jones Surai , Savage Heidi M. , Scaltriti Maurizio , Wilson Timothy R. , Wei Michael C. , Hyman David M.
Published: April 2023

Supplementary Tables
Supplementary Figure 6 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Authors: Collins Denis M. , Madden Stephen F. , Gaynor Nicola , AlSultan Dalal , Le Gal Marion , Eustace Alex J. , Gately Kathy A. , Hughes Clare , Davies Anthony M. , Mahgoub Thamir , Ballot Jo , Toomey Sinead , O'Connor Darran P. , Gallagher William M. , Holmes Frankie A. , Espina Virginia , Liotta Lance , Hennessy Bryan T. , O'Byrne Kenneth J. , Hasmann Max , Bossenmaier Birgit , O'Donovan Norma , Crown John
Published: April 2023

MFI comparison at T0 and T6 for T47D/MCF-7
Supplementary Tables S1-S5 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Authors: Kalbasi Anusha , Kamrava Mitchell , Chu Fang-I , Telesca Donatello , Van Dams Ritchell , Yang Yingli , Ruan Dan , Nelson Scott D. , Dry Sarah M. , Hernandez Jackie , Chmielowski Bartosz , Singh Arun S. , Bukata Susan V. , Bernthal Nicholas M. , Steinberg Michael L. , Weidhaas Joanne B. , Eilber Fritz C.
Published: April 2023

Supplementary Tables S1-S5
Table S3 from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Authors: Zhang Hongyi , Liu Longchao , Zhang Jian , Chen Jiahui , Ye Jianfeng , Shukla Sachet , Qiao Jian , Zhan Xiaowei , Chen Hao , Wu Catherine J. , Fu Yang-Xin , Li Bo
Published: April 2023

HLA genotype information for the 9 individuals with HSFX1 expression.
Supplementary Figure 1 from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
Authors: Rahma Osama E. , Reuss Joshua E. , Giobbie-Hurder Anita , Shoja E Razavi Ghazaleh , Abu-Shawer Osama , Mehra Pooja , Gupta Seema , Simon Richard , Khleif Samir N.
Published: April 2023

Supplementary Figure 1
Supplementary Data 1 from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Authors: Zhang Hongyi , Liu Longchao , Zhang Jian , Chen Jiahui , Ye Jianfeng , Shukla Sachet , Qiao Jian , Zhan Xiaowei , Chen Hao , Wu Catherine J. , Fu Yang-Xin , Li Bo
Published: April 2023

Datasets generated in this study including: Supplementary file -15_antigens. Information for the 15 selected antigens for methodology performance evaluation. Supplementary file -TCRcount_correlation. Summary of association analysis between gene expression levels and clustered CDR3 count in each individual. Supplementary file -New_Group_genes. Summary of differential gene expression analysis between the single cells from new defined group and others, with fold change and FDR estimations. Supplementary file -Trm2vsTrm1_DETable. The differential expressed genes of Trm2vsTrm1. Supplementary file -CDR3_Cluster_Gene_Correlation: Summary of differential gene expression analysis between each CDR3 cluster and other TCGA tumors, with fold change and FDR estimations. Supplementary file -TCGAtcrClustered_iSMART. 4.6K iSMART clustered TCRs from TCGA tumor RNA-seq data.
Figure S4 from Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models
Authors: Yang Gang , Guan Wenfang , Cao Zhe , Guo Wenbo , Xiong Guangbing , Zhao Fangyu , Feng Mengyu , Qiu Jiangdong , Liu Yueze , Zhang Michael Q. , You Lei , Zhang Taiping , Zhao Yupei , Gu Jin
Published: April 2023

KEGG enrichment analysis for DEmRNAs
Supplementary Figure 1 from Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Authors: Vidal Joana , Casadevall David , Bellosillo Beatriz , Pericay Carles , Garcia-Carbonero Rocio , Losa Ferran , Layos Laia , Alonso Vicente , Capdevila Jaume , Gallego Javier , Vera Ruth , Salud Antonieta , Martin-Richard Marta , Nogué Miguel , Cillán Elena , Maurel Joan , Faull Iris , Raymond Victoria , Fernández-Martos Carlos , Montagut Clara
Published: April 2023

Kaplan-Meier estimates of disease-free survival and overall survival according to pCR and NAR score in the sub-study cohort A. Disease-free survival according to pCR B. Overall survival according pCR C. Disease-free survival according to NAR score D. Overall survival according NAR score
Supplementary information from MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions
Authors: Sato Hiroki , Schoenfeld Adam J. , Siau Evan , Lu Yue Christine , Tai Huichun , Suzawa Ken , Kubota Daisuke , Lui Allan J.W. , Qeriqi Besnik , Mattar Marissa , Offin Michael , Sakaguchi Masakiyo , Toyooka Shinichi , Drilon Alexander , Rosen Neal X. , Kris Mark G. , Solit David , De Stanchina Elisa , Davare Monika A. , Riely Gregory J. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary case reports, supplementary materials and methods and supplementary figure legends are included.
Supplementary Figures S1-S5 from ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
Authors: Myojin Yuta , Kodama Takahiro , Maesaka Kazuki , Motooka Daisuke , Sato Yu , Tanaka Satoshi , Abe Yuichi , Ohkawa Kazuyoshi , Mita Eiji , Hayashi Yoshito , Hikita Hayato , Sakamori Ryotaro , Tatsumi Tomohide , Taguchi Ayumu , Eguchi Hidetoshi , Takehara Tetsuo
Published: April 2023

Supplementary Figures S1-S5
Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Authors: Wick Antje , Bähr Oliver , Schuler Martin , Rohrberg Kristoffer , Chawla Sant P. , Janku Filip , Schiff David , Heinemann Volker , Narita Yoshitaka , Lenz Heinz-Josef , Ikeda Masafumi , Ando Yuichi , Wick Wolfgang , Steinbach Joachim P. , Burger Michael C. , Wenger Katharina , Lassen Ulrik , Sankhala Kamalesh K. , Roggia Cristiana , Genvresse Isabelle , Munhoz Catya , Rentzsch Christine , Reschke Susanne , Langer Simon , Wagner Markus , Kaulfuss Stefan , Cai Charles , Lagkadinou Eleni , Jeffers Michael , Peña Carol , Tabatabai Ghazaleh
Published: April 2023

Supplementary Figure S1. Geometric mean plasma concentration-time profiles of BAY1436032 at dose levels of 150 mg to 1500 mg.
Figure S1 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Study flow chart
Supplementary Figure 1 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Authors: Davids Matthew S. , Kuss Bryone J. , Hillmen Peter , Montillo Marco , Moreno Carol , Essell James , Lamanna Nicole , Nagy Zsolt , Tam Constantine S. , Stilgenbauer Stephan , Ghia Paolo , Delgado Julio , Lustgarten Stephanie , Weaver David T. , Youssoufian Hagop , Jäger Ulrich
Published: April 2023

Figure S1 displays probability of progression-free survival over time in the study population and in the subgroup of patients with del(17p) and/or TP53 mutations that received ofatumumab while participating in the parent DUO study before crossover
Supplementary Figure S1-S3 from In Vivo Tracking of Adoptively Transferred Natural Killer Cells in Rhesus Macaques Using 89Zirconium-Oxine Cell Labeling and PET Imaging
Authors: Sato Noriko , Stringaris Kate , Davidson-Moncada Jan K. , Reger Robert , Adler Stephen S. , Dunbar Cynthia , Choyke Peter L. , Childs Richard W.
Published: April 2023

Fig. S1. Zr-89 oxine labeling does not alter NK cell phenotype. Fig. S2. PET/CT reveals low bone marrow homing of NK cells. Fig. S3. CD34+ HSPCs home to the bone marrow.
Fig.S1 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases
Authors: Di Giacomo Anna Maria , Chiarion-Sileni Vanna , Del Vecchio Michele , Ferrucci Pier Francesco , Guida Michele , Quaglino Pietro , Guidoboni Massimo , Marchetti Paolo , Cutaia Ornella , Amato Giovanni , Covre Alessia , Camerini Roberto , Calabrò Luana , Valente Monica , Giannarelli Diana , Mandalà Mario , Maio Michele
Published: April 2023

Study design and treatment schedule. Patients in either the ipilimumab plus fotemustine arm or the ipilimumab plus nivolumab arm could continue maintenance treatment until disease progression, excessive toxicity, or patient refusal
Figure S5 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Authors: Ranganathan Raghuveer , Shou Peishun , Ahn Sarah , Sun Chuang , West John , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

CD19-T cells show equivalent antitumor activity in a patient-derived xenograft (PDX) mantle cell lymphoma model in vivo.
Figure S2 from CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells
Authors: Ranganathan Raghuveer , Shou Peishun , Ahn Sarah , Sun Chuang , West John , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

CAR targeting
Supplementary Table 1 from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms
Authors: Sharda Anish V. , Bogue Thomas , Barr Alexandra , Mendez Lourdes M. , Flaumenhaft Robert , Zwicker Jeffrey I.
Published: April 2023

Details of the thromboembolic events in the study
Supplementary Figure 3 from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms
Authors: Sharda Anish V. , Bogue Thomas , Barr Alexandra , Mendez Lourdes M. , Flaumenhaft Robert , Zwicker Jeffrey I.
Published: April 2023

Comparison of standard thrombosis risk factors with plasma PDI and development of thromboembolic events in MPN
Supplementary Table 3 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Authors: Sum Eva , Rapp Moritz , Fröbel Philipp , Le Clech Marine , Dürr Harald , Giusti Anna Maria , Perro Mario , Speziale Dario , Kunz Leo , Menietti Elena , Brünker Peter , Hopfer Ulrike , Lechmann Martin , Sobieniecki Andrzej , Appelt Birte , Adelfio Roberto , Nicolini Valeria , Freimoser-Grundschober Anne , Jordaan Whitney , Labiano Sara , Weber Felix , Emrich Thomas , Christen François , Essig Birgit , Romero Pedro , Trumpfheller Christine , Umaña Pablo
Published: April 2023

Additional data of cynomolgus monkey study showing body weight and plasma cytokine levels over the course of the study
Table S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Authors: Segal Neil H. , Cercek Andrea , Ku Geoffrey , Wu Abraham J. , Rimner Andreas , Khalil Danny N. , Reidy-Lagunes Diane , Cuaron John , Yang T. Jonathan , Weiser Martin R. , Romesser Paul B. , Stadler Zsofia K. , Varghese Anna M. , Ganesh Karuna , Yaeger Rona , Connell Louise C. , Faleck David , Abou-Alfa Ghassan K. , Mcauliffe Kathleen C. , Vaiskauskas Pamela , Solter Mark L. , Ogle Martinique , Adamow Matthew J. , Holland Aliya , Vedantam Pallavi , Wong Phillip , Merghoub Taha , Vakiani Efsevia , Hollmann Travis J. , Juluru Krishna , Chou Joanne F. , Capanu Marinela , Erinjeri Joseph , Solomon Stephen , Yamada Yoshiya , Kemeny Nancy , Crane Christopher H. , Saltz Leonard B.
Published: April 2023

Radiation treatment summary
Figure S2 from Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Authors: Ellingson Benjamin M. , Sampson John , Achrol Achal Singh , Aghi Manish K. , Bankiewicz Krystof , Wang Chencai , Bexon Martin , Brem Steven , Brenner Andrew , Chowdhary Sajeel , Floyd John R. , Han Seunggu , Kesari Santosh , Randazzo Dina , Vogelbaum Michael A. , Vrionis Frank , Zabek Miroslaw , Butowski Nicholas , Coello Melissa , Merchant Nina , Merchant Fahar
Published: April 2023

mRANO Response Rubric.
Supplementary Figure 2 from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Authors: Petroni Giulia , Buqué Aitziber , Yamazaki Takahiro , Bloy Norma , Liberto Maurizio Di , Chen-Kiang Selina , Formenti Silvia C. , Galluzzi Lorenzo
Published: April 2023

Superior short- and long-term cell cycle control by RT followed palbociclib in human TNBC cells
Supplementary Figure 1 from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Authors: Petroni Giulia , Buqué Aitziber , Yamazaki Takahiro , Bloy Norma , Liberto Maurizio Di , Chen-Kiang Selina , Formenti Silvia C. , Galluzzi Lorenzo
Published: April 2023

RT followed by palbociclib mediates robust cytostatic effects against human TNBC cells
Supplementary Data from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Authors: Petroni Giulia , Buqué Aitziber , Yamazaki Takahiro , Bloy Norma , Liberto Maurizio Di , Chen-Kiang Selina , Formenti Silvia C. , Galluzzi Lorenzo
Published: April 2023

Legends to Supplementary Figures
Figure S9 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses by chemotherapy (yes vs. no), DeepPET-OPSCC risk category, discovery, TCIA test, and the entire cohort with known HPV
Supplementary Data from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Authors: Jolissaint Joshua S. , Soares Kevin C. , Seier Kenneth P. , Kundra Ritika , Gönen Mithat , Shin Paul J. , Boerner Thomas , Sigel Carlie , Madupuri Ramyasree , Vakiani Efsevia , Cercek Andrea , Harding James J. , Kemeny Nancy E. , Connell Louise C. , Balachandran Vinod P. , D'Angelica Michael I. , Drebin Jeffrey A. , Kingham T. Peter , Wei Alice C. , Jarnagin William R.
Published: April 2023

Supplementary Data (Figures in separate files)
Supplementary Table 2 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Table 2
Supplementary Legends from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Authors: Bockorny Bruno , Macarulla Teresa , Semenisty Valerya , Borazanci Erkut , Feliu Jaime , Ponz-Sarvise Mariano , Abad David Gutierrez , Oberstein Paul , Alistar Angela , Muñoz Andres , Geva Ravit , Guillén-Ponce Carmen , Fernandez Mercedes Salgado , Peled Amnon , Chaney Marya , Gliko-Kabir Irit , Shemesh-Darvish Liron , Ickowicz Debby , Sorani Ella , Kadosh Shaul , Vainstein-Haras Abi , Hidalgo Manuel
Published: April 2023

Supplementary Legends
Table S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

Demographic data for the PD-1 treated subset.
Table S2 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Authors: Shoushtari Alexander N. , Chatila Walid K. , Arora Arshi , Sanchez-Vega Francisco , Kantheti Havish S. , Rojas Zamalloa Jorge A. , Krieger Penina , Callahan Margaret K. , Betof Warner Allison , Postow Michael A. , Momtaz Parisa , Nair Suresh , Ariyan Charlotte E. , Barker Christopher A. , Brady Mary Susan , Coit Daniel G. , Rosen Neal , Chapman Paul B. , Busam Klaus J. , Solit David B. , Panageas Katherine S. , Wolchok Jedd D. , Schultz Nikolaus
Published: April 2023

Clinical data for each sequenced sample.
Supp Figure 4 from Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Authors: Garcia-Moure Marc , Gonzalez-Huarriz Marisol , Labiano Sara , Guruceaga Elizabeth , Bandres Eva , Zalacain Marta , Marrodan Lucia , de Andrea Carlos , Villalba Maria , Martinez-Velez Naiara , Laspidea Virginia , Puigdelloses Montse , Gallego Perez-Larraya Jaime , Iñigo-Marco Ignacio , Stripecke Renata , Chan Jennifer A. , Raabe Eric H. , Kool Marcel , Gomez-Manzano Candelaria , Fueyo Juan , Patiño-García Ana , Alonso Marta M.
Published: April 2023

Supp Figure 4 Detection of Delta-24-RGD replication at late stages of disease.
Supplementary Table 1 from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Table S1
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Fig. S4 DD-mediated depletion of Tregs improves T cell proliferation.
Supplementary Data from HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
Authors: Leung Eric , Han Kathy , Zou Jinfeng , Zhao Zhen , Zheng Yangqiao , Wang Ting Ting , Rostami Ariana , Siu Lillian L. , Pugh Trevor J. , Bratman Scott V.
Published: April 2023

Supplementary Data from HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
Supplementary Data from IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Authors: Thibodeaux Suzanne R. , Barnett Brian B. , Pandeswara Srilakshmi , Wall Shawna R. , Hurez Vincent , Dao Vinh , Sun Lishi , Daniel Benjamin J. , Brumlik Michael J. , Drerup Justin , Padrón Álvaro , Whiteside Teresa , Kryczek Ilona , Zou Weiping , Curiel Tyler J.
Published: April 2023

Description of each individual supplemental fig or table
Supplementary Figure 3 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Sarker Debashis , Dawson Nancy A. , Aparicio Ana M. , Dorff Tanya B. , Pantuck Allan J. , Vaishampayan Ulka N. , Henson Lynn , Vasist Lakshmi , Roy-Ghanta Sumita , Gorczyca Michele , York Whitney , Ganji Gopinath , Tolson Jerry , de Bono Johann S.
Published: April 2023

LLQ=15.6 mg/mL. LLQ shown by horizontal reference line. N=1 for 400 mg GSK2636771 plus 160 mg enzalutamide 160 mg escalation cohort. LLQ, lower limit of quantification.